KMP also yielded positive results in colon cancer, inhibiting cyclin D-dependent kinase 2 (CDK2) and cyclin D-dependent kinase 4 (CDK4) activities and inducing cell cycle arrest both at G1 (after 6 h of treatment) and G2/M (after 12 h) [43], as well as reducing glucose consumption [76], cell viability [24] (Liu et al., 2019), proliferation [14,45,70], and invasion and migration [59]. This evidence concerns the gene CDK2 and colonic neoplasm.